Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ALNY
- CUSIP: 02043Q10
- Web: www.alnylam.com
Capitalization:- Market Cap: $6.45 billion
- Outstanding Shares: 86,190,000
Average Prices:- 50 Day Moving Avg: $55.05
- 200 Day Moving Avg: $47.54
- 52 Week Range: $31.38 - $80.11
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -14.91
- P/E Growth: -0.29
Sales & Book Value:- Annual Revenue: $58.77 million
- Price / Sales: 109.80
- Book Value: $9.65 per share
- Price / Book: 7.76
Profitability:- EBIDTA: ($407,540,000.00)
- Net Margins: -869.63%
- Return on Equity: -37.25%
- Return on Assets: -30.67%
Debt:- Debt-to-Equity Ratio: 0.15%
- Current Ratio: 9.14%
- Quick Ratio: 9.14%
Misc:- Average Volume: 1.03 million shs.
- Beta: 2.69
- Short Ratio: 12.01
Frequently Asked Questions for Alnylam Pharmaceuticals (NASDAQ:ALNY)
What is Alnylam Pharmaceuticals' stock symbol?
Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."
How were Alnylam Pharmaceuticals' earnings last quarter?
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its quarterly earnings results on Friday, May, 5th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.22) by $0.03. The business earned $19 million during the quarter, compared to the consensus estimate of $22.91 million. Alnylam Pharmaceuticals had a negative net margin of 869.63% and a negative return on equity of 37.25%. The company's quarterly revenue was up 160.3% compared to the same quarter last year. During the same period last year, the firm earned ($1.21) EPS. View Alnylam Pharmaceuticals' Earnings History.
When will Alnylam Pharmaceuticals make its next earnings announcement?
Where is Alnylam Pharmaceuticals' stock going? Where will Alnylam Pharmaceuticals' stock price be in 2017?
17 brokerages have issued twelve-month target prices for Alnylam Pharmaceuticals' shares. Their predictions range from $36.00 to $118.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $72.65 in the next year. View Analyst Ratings for Alnylam Pharmaceuticals.
What are analysts saying about Alnylam Pharmaceuticals stock?
Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
- 1. Chardan Capital analysts commented, "We now seen Alnylam as the leader in the clinical HBV RNAi therapy space. As discussed in our 14 October 2016 company note for Arbutus (Buy), we believe ARB-1467 has demonstrated at best mediocre phase IIa results that were predictable based on inferior preclinical data relative to Alnylam’s RNAi asset, ALN-HBV . Additionally, ALN-HBV has a favorable dosing route in subcutaneous delivery compared to Arbutus’ ARB-1467 and ARB-1740, which are administered by intravenous injection. With Arrowhead moving to preclinical development in HBV , we now view Alnylam as the leader in the space." (11/30/2016)
- 2. According to Zacks Investment Research, "Alnylam is a development-stage biopharmaceutical company focused on the development of RNAi-based therapeutics. The company expects to achieve the profile of three marketed products by the end of 2020. Investor focus should be on the company's progress with its late-stage pipeline candidate, patisiran. Meanwhile, Alnylam’s RNAi technology has allowed the company to ink collaborations with leading pharmaceutical and life sciences companies like Novartis, Roche, Monsanto and Sanofi. These deals will not only provide it with funds but also take its RNAi technology outside the core focus area. Estimate movement has been mixed lately ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters. However, the discontinuation of the phase III ENDEAVOUR study on revusiran, following the Data Monitoring Committee’s recommendation (DMC) is disappointing." (10/25/2016)
- 3. Needham & Company LLC analysts commented, "Alnylam announced additional data from its ongoing fitusiran Phase 1/2 trial in Hemophilia. Emerging safety and efficacy profile is consistent w/ prior clinical data and point to a differentiated once-monthly agent. Phase 3 initiation, however, has been pushed into 2017 (was 2H16). Regulators are seeking additional information around dose. Mgmt expects to complete dose-escalation in Hemophilia pts w/ Inhibitors later this yr." (7/25/2016)
Who are some of Alnylam Pharmaceuticals' key competitors?
Some companies that are related to Alnylam Pharmaceuticals include Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Exelixis (EXEL), BIO-TECHNE Corp (TECH), Kite Pharma (KITE), Galapagos NV (GLPG), Opko Health (OPK), ACADIA Pharmaceuticals (ACAD), bluebird bio (BLUE), China Biologic Products (CBPO), Nektar Therapeutics (NKTR), Intercept Pharmaceuticals (ICPT), Intrexon Corp (XON), Juno Therapeutics (JUNO), SAGE Therapeutics (SAGE), Clovis Oncology (CLVS) and Ultragenyx Pharmaceutical (RARE).
Who owns Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (0.00%), Wellington Management Group LLP (0.00%), Vanguard Group Inc. (0.00%), BlackRock Inc. (0.00%), Baillie Gifford & Co. (0.00%) and State Street Corp (2.51%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, David E I Pyott, David-Alexandre C Gros, John Maraganore, Kevin P Starr, Michael Mason, Michael W Bonney, Philip A Sharp and Sanofi. View Institutional Ownership Trends for Alnylam Pharmaceuticals.
Who sold Alnylam Pharmaceuticals stock? Who is selling Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Legal & General Group Plc, State Street Corp, TimesSquare Capital Management LLC, Morgan Stanley, UBS Group AG, First Trust Advisors LP, Frontier Capital Management Co. LLC and State of Wisconsin Investment Board. Company insiders that have sold Alnylam Pharmaceuticals stock in the last year include Akshay Vaishnaw, John Maraganore, Michael Mason and Philip A Sharp. View Insider Buying and Selling for Alnylam Pharmaceuticals.
Who bought Alnylam Pharmaceuticals stock? Who is buying Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Perceptive Advisors LLC, Rockefeller Financial Services Inc., Blue Ridge Capital L.L.C., Pictet Asset Management Ltd., Russell Investments Group Ltd., Vanguard Group Inc. and Janus Capital Management LLC. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include David E I Pyott, David-Alexandre C Gros, Michael W Bonney and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.
How do I buy Alnylam Pharmaceuticals stock?
Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Alnylam Pharmaceuticals stock cost?
One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $74.87.
Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)Earnings History by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | | | | | | | | |
| 5/5/2017 | Q1 2017 | ($1.22) | ($1.25) | $22.91 million | $19.00 million | View | N/A |  |
| 2/8/2017 | Q416 | ($1.34) | ($1.32) | $10.66 million | $17.50 million | View | Listen | |
| 11/2/2016 | Q316 | ($1.14) | ($1.21) | $9.14 million | $13.70 million | View | N/A | |
| 8/4/2016 | Q216 | ($1.24) | ($1.05) | $8.09 million | $8.70 million | View | Listen | |
| 5/2/2016 | Q116 | ($1.05) | ($1.21) | $7.79 million | $7.30 million | View | Listen | |
| 2/11/2016 | Q415 | ($0.96) | ($1.07) | $9.59 million | $7.60 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.91) | ($0.91) | $7.55 million | $6.30 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.75) | ($0.85) | $12.64 million | $8.69 million | View | N/A | |
| 5/7/2015 | Q115 | ($0.65) | ($0.62) | $15.40 million | $18.51 million | View | N/A | |
| 2/12/2015 | Q414 | ($0.66) | ($0.28) | $13.10 million | $24.00 million | View | N/A | |
| 11/5/2014 | Q314 | ($0.63) | ($0.58) | $8.93 million | $11.00 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.54) | ($0.63) | $9.36 million | $7.30 million | View | N/A | |
| 5/8/2014 | Q114 | ($1.18) | ($0.39) | $10.80 million | $8.30 million | View | N/A | |
| 2/19/2014 | Q413 | ($0.45) | ($0.51) | $9.98 million | $10.80 million | View | N/A | |
| 11/6/2013 | Q313 | ($0.39) | ($0.48) | $8.64 million | $9.00 million | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.35) | ($0.29) | $8.99 million | $8.70 million | View | Listen | |
| 5/6/2013 | Q1 2013 | ($0.29) | ($0.15) | $15.56 million | $18.60 million | View | Listen | |
| 2/7/2013 | Q4 2012 | ($1.45) | ($1.20) | $15.82 million | $8.50 million | View | Listen | |
| 11/5/2012 | Q312 | ($0.32) | ($0.31) | $17.30 million | $16.80 million | View | N/A | |
| 8/6/2012 | | ($0.21) | ($0.25) | | | View | N/A | |
| 5/3/2012 | | ($0.35) | ($0.25) | | | View | N/A | |
| 2/9/2012 | | ($0.33) | ($0.33) | | | View | N/A | |
| 11/1/2011 | | ($0.35) | ($0.31) | | | View | N/A | |
| 8/1/2011 | | ($0.36) | ($0.33) | | | View | N/A | |
| 5/2/2011 | | ($0.30) | ($0.38) | | | View | N/A | |
| 2/17/2011 | | ($0.35) | ($0.16) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)2017 EPS Consensus Estimate: ($5.23)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($1.36) | ($1.30) | ($1.33) |
| Q2 2017 | 2 | ($1.36) | ($1.30) | ($1.33) |
| Q3 2017 | 2 | ($1.36) | ($1.21) | ($1.29) |
| Q4 2017 | 2 | ($1.37) | ($1.19) | ($1.28) |
(Data provided by Zacks Investment Research)
Dividend History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Alnylam Pharmaceuticals (NASDAQ:ALNY)Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 88.70%
Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/16/2017 | Michael Mason | VP | Sell | 9,375 | $70.00 | $656,250.00 | |
| 5/15/2017 | Akshay Vaishnaw | SVP | Sell | 43,750 | $65.00 | $2,843,750.00 | |
| 1/25/2017 | Philip A Sharp | Director | Sell | 15,000 | $37.95 | $569,250.00 | |
| 1/18/2017 | Philip A Sharp | Director | Sell | 15,000 | $37.83 | $567,450.00 | |
| 11/30/2016 | Akshay Vaishnaw | CMO | Sell | 29,165 | $44.99 | $1,312,133.35 | |
| 10/13/2016 | David E I Pyott | Director | Buy | 27,900 | $37.00 | $1,032,300.00 | |
| 7/20/2016 | John Maraganore | CEO | Sell | 30,151 | $64.69 | $1,950,468.19 | |
| 4/20/2016 | John Maraganore | CEO | Sell | 30,151 | $67.46 | $2,033,986.46 | |
| 3/9/2016 | Michael W Bonney | Director | Buy | 2,000 | $58.36 | $116,720.00 | |
| 2/22/2016 | David-Alexandre C Gros | SVP | Buy | 1,000 | $62.75 | $62,750.00 | |
| 2/1/2016 | Sanofi | Major Shareholder | Buy | 205,030 | $69.75 | $14,300,842.50 | |
| 1/20/2016 | John Maraganore | CEO | Sell | 30,152 | $71.78 | $2,164,310.56 | |
| 12/4/2015 | Philip A. Sharp | Director | Sell | 30,000 | $109.00 | $3,270,000.00 | |
| 12/2/2015 | John Maraganore | CEO | Sell | 58,689 | $104.87 | $6,154,715.43 | |
| 11/20/2015 | John Maraganore | CEO | Sell | 58,690 | $102.88 | $6,038,027.20 | |
| 11/12/2015 | Kevin P. Starr | Director | Sell | 75,000 | $103.89 | $7,791,750.00 | |
| 6/16/2015 | Akshay Vaishnaw | CMO | Sell | 8,750 | $128.83 | $1,127,262.50 | |
| 5/12/2015 | Michael W Bonney | Director | Buy | 2,000 | $112.16 | $224,320.00 | |
| 4/21/2015 | Paul Schimmel | Director | Sell | 10,000 | $130.02 | $1,300,200.00 | |
| 3/19/2015 | Dennis A Ausiello | Director | Sell | 5,000 | $120.00 | $600,000.00 | |
| 3/17/2015 | Akshay Vaishnaw | CMO | Sell | 8,750 | $116.86 | $1,022,525.00 | |
| 1/29/2015 | Sanofi | Major Shareholder | Buy | 97,118 | $95.00 | $9,226,210.00 | |
| 1/26/2015 | John Maraganore | CEO | Buy | 10,000 | $95.00 | $950,000.00 | |
| 1/26/2015 | Steven M Paul | Director | Buy | 1,000 | $95.00 | $95,000.00 | |
| 12/19/2014 | Barry E Greene | COO | Sell | 11,200 | $100.00 | $1,120,000.00 | |
| 12/16/2014 | Akshay Vaishnaw | EVP | Sell | 10,626 | $93.60 | $994,593.60 | |
| 12/15/2014 | Michael Mason | VP | Sell | 22,162 | $97.50 | $2,160,795.00 | |
| 11/18/2014 | Laurence Reid | SVP | Sell | 10,000 | $90.67 | $906,700.00 | |
| 11/17/2014 | Barry E Greene | COO | Sell | 33,200 | $89.63 | $2,975,716.00 | |
| 10/28/2014 | Paul Schimmel | Director | Sell | 15,000 | $95.00 | $1,425,000.00 | |
| 10/22/2014 | Dennis A Ausiello | Director | Sell | 5,000 | $90.00 | $450,000.00 | |
| 10/13/2014 | Philip A Sharp | Director | Sell | 110,000 | $85.00 | $9,350,000.00 | |
| 9/25/2014 | Kevin P Starr | Director | Sell | 90,000 | $78.09 | $7,028,100.00 | |
| 9/24/2014 | Kevin P Starr | Director | Sell | 45,000 | $79.08 | $3,558,600.00 | |
| 9/18/2014 | John Maraganore | CEO | Sell | 113,668 | $77.71 | $8,833,140.28 | |
| 9/16/2014 | Akshay Vaishnaw | EVP | Sell | 10,625 | $72.04 | $765,425.00 | |
| 8/18/2014 | Laurence Reid | SVP | Sell | 13,500 | $67.34 | $909,090.00 | |
| 6/26/2014 | John Maraganore | CEO | Sell | 113,668 | $65.45 | $7,439,570.60 | |
| 6/17/2014 | Akshay Vaishnaw | EVP | Sell | 10,625 | $69.82 | $741,837.50 | |
| 5/21/2014 | John Clarke | Director | Sell | 35,000 | $53.80 | $1,883,000.00 | |
| 5/19/2014 | Laurence Reid | SVP | Sell | 13,500 | $57.83 | $780,705.00 | |
| 5/15/2014 | John Maraganore | CEO | Sell | 113,668 | $56.73 | $6,448,385.64 | |
| 3/25/2014 | Sanofi | major shareholder | Buy | 344,448 | $66.88 | $23,036,682.24 | |
| 3/18/2014 | Akshay Vaishnaw | EVP | Sell | 32,769 | $73.95 | $2,423,267.55 | |
| 2/19/2014 | Laurence Reid | SVP | Sell | 20,400 | $80.06 | $1,633,224.00 | |
| 1/24/2014 | Akshay Vaishnaw | EVP | Sell | 7,890 | $85.75 | $676,567.50 | |
| 1/13/2014 | Paul Schimmel | Director | Sell | 15,000 | $85.36 | $1,280,400.00 | |
| 12/20/2013 | Paul Schimmel | Director | Sell | 15,000 | $65.00 | $975,000.00 | |
| 12/17/2013 | Akshay Vaishnaw | EVP | Sell | 33,480 | $60.72 | $2,032,905.60 | |
| 10/22/2013 | Paul Schimmel | Director | Sell | 15,000 | $60.00 | $900,000.00 | |
| 9/11/2013 | John Maraganore | CEO | Sell | 58,947 | $55.50 | $3,271,558.50 | |
| 9/10/2013 | Akshay Vaishnaw | EVP | Sell | 6,250 | $57.48 | $359,250.00 | |
| 8/14/2013 | John Maraganore | CEO | Sell | 60,000 | $48.97 | $2,938,200.00 | |
| 7/12/2013 | Michael Mason | VP | Sell | 14,200 | $50.00 | $710,000.00 | |
| 7/10/2013 | John Maraganore | CEO | Sell | 60,000 | $37.11 | $2,226,600.00 | |
| 7/1/2013 | Michael Mason | VP | Sell | 27,000 | $32.00 | $864,000.00 | |
| 6/17/2013 | Michael Mason | VP | Sell | 23,625 | $29.93 | $707,096.25 | |
| 6/11/2013 | Akshay Vaishnaw | EVP | Sell | 15,000 | $31.08 | $466,200.00 | |
| 5/28/2013 | Barry E Greene | COO | Sell | 22,822 | $30.00 | $684,660.00 | |
| 5/28/2013 | Laurence Reid | SVP | Sell | 5,000 | $30.00 | $150,000.00 | |
| 3/26/2013 | Kevin P Starr | Director | Sell | 52,631 | $23.49 | $1,236,302.19 | |
| 1/22/2013 | Philip A Sharp | Director | Buy | 4,967 | $20.13 | $99,985.71 | |
(Data available from 1/1/2013 forward)
Headline Trends for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Latest Headlines for Alnylam Pharmaceuticals (NASDAQ:ALNY)
| Source: |
|
| Date | Headline |
|---|
 | Alnylam Pharmaceuticals, Inc. (ALNY) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 23 at 4:16 PM |
| Leerink Swann Comments on Alnylam Pharmaceuticals, Inc.'s FY2018 Earnings (ALNY)
www.americanbankingnews.com - May 18 at 2:48 PM |
| Akshay Vaishnaw Sells 43,750 Shares of Alnylam Pharmaceuticals, Inc. (ALNY) Stock
www.americanbankingnews.com - May 17 at 10:29 PM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Given a $80.00 Price Target by Ladenburg Thalmann Financial Services Analysts
www.americanbankingnews.com - May 17 at 8:32 PM |
| Michael Mason Sells 9,375 Shares of Alnylam Pharmaceuticals, Inc. (ALNY) Stock
www.americanbankingnews.com - May 17 at 7:47 PM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rating Reaffirmed by Goldman Sachs Group Inc
www.americanbankingnews.com - May 17 at 2:08 PM |
| Credit Suisse Group AG Reaffirms Outperform Rating for Alnylam Pharmaceuticals, Inc. (ALNY)
www.americanbankingnews.com - May 17 at 1:32 PM |
 | Alnylam Pharmaceuticals Reaches Analyst Target Price
www.nasdaq.com - May 17 at 12:30 PM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Earns Market Perform Rating from Leerink Swann
www.americanbankingnews.com - May 17 at 12:16 PM |
| Alnylam Pharmaceuticals' (ALNY) "Outperform" Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - May 17 at 10:20 AM |
 | Alnylam Pharmaceuticals (ALNY) Looks Good: Stock Jumps 16.3%
finance.yahoo.com - May 16 at 3:30 PM |
 | Why Ionis Results Today Support A Pair Trade With Alnylam - Benzinga
www.benzinga.com - May 16 at 7:23 AM |
 | Why Ionis Pharmaceuticals Inc Tanked and Alnylam Pharmaceuticals, Inc. Is Soaring Today - Motley Fool
www.fool.com - May 16 at 7:23 AM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Lowered to "Buy" at Vetr Inc.
www.americanbankingnews.com - May 16 at 12:34 AM |
| Why Ionis Results Today Support A Pair Trade With Alnylam
www.benzinga.com - May 15 at 3:28 PM |
| Why Ionis Results Today Support A Pair Trade With Alnylam
www.benzinga.com - May 15 at 3:28 PM |
| How Ionis Helped Rival Alnylam — But Tanked Itself — On A Key Trial
finance.yahoo.com - May 15 at 3:28 PM |
| How Ionis Helped Rival Alnylam — But Tanked Itself — On A Key Trial
finance.yahoo.com - May 15 at 3:28 PM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Given a $118.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - May 15 at 2:34 PM |
| Chardan Capital Raises Alnylam Pharmaceuticals, Inc. (ALNY) Price Target to $110.00
www.americanbankingnews.com - May 15 at 11:26 AM |
| Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Financial Officer
finance.yahoo.com - May 12 at 9:01 PM |
| Alnylam Pharmaceuticals, Inc. Earnings: All Eyes on APOLLO - Motley Fool
www.fool.com - May 12 at 4:00 PM |
| Alnylam to Webcast Presentations at Upcoming May Investor Conferences
finance.yahoo.com - May 12 at 1:46 AM |
| ETFs with exposure to Alnylam Pharmaceuticals, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 8:45 PM |
 | Alnylam to Webcast Presentations at Upcoming May Investor ... - Business Wire (press release)
www.businesswire.com - May 11 at 1:41 AM |
| Edited Transcript of ALNY earnings conference call or presentation 5-May-17 12:30pm GMT
finance.yahoo.com - May 10 at 8:39 PM |
| Alnylam Pharmaceuticals, Inc. Earnings: All Eyes on APOLLO
www.fool.com - May 10 at 4:29 PM |
 | CFO Moves: Alnylam Pharmaceuticals - Wall Street Journal (subscription) (blog)
blogs.wsj.com - May 10 at 9:25 AM |
 | BRIEF-Alnylam Pharmaceuticals appoints Manmeet Soni as chief financial officer - Reuters
www.reuters.com - May 9 at 3:27 PM |
| Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 3:27 PM |
| Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders
finance.yahoo.com - May 9 at 9:20 AM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Earns "Hold" Rating from Credit Suisse Group AG
www.americanbankingnews.com - May 9 at 7:38 AM |
| Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y - Nasdaq
www.nasdaq.com - May 8 at 3:25 PM |
| Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y
finance.yahoo.com - May 8 at 3:25 PM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rating Reaffirmed by Morgan Stanley
www.americanbankingnews.com - May 8 at 1:22 PM |
 | Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 6 at 3:55 PM |
| Chardan Capital Reiterates Buy Rating for Alnylam Pharmaceuticals, Inc. (ALNY)
www.americanbankingnews.com - May 5 at 10:50 PM |
 | EARNINGS SUMMARY: Details of Alnylam Pharmaceuticals Inc. Q1 Earnings Report
www.rttnews.com - May 5 at 8:31 PM |
| Alnylam Pharmaceuticals, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 5 at 8:31 PM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Posts Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - May 5 at 3:32 PM |
| Alnylam Pharmaceuticals Reports First Quarter 2017 Financial ... - Business Wire (press release)
www.businesswire.com - May 5 at 3:29 PM |
| Earnings Reaction History: Alnylam Pharmaceuticals Inc., 40.0% Follow-Through Indicator, 7.6% Sensitive - Nasdaq
www.nasdaq.com - May 5 at 3:29 PM |
| Investor Network: Alnylam Pharmaceuticals, Inc to Host Earnings Call
finance.yahoo.com - May 5 at 3:28 PM |
| Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity
finance.yahoo.com - May 5 at 3:28 PM |
| Alnylam reports 1Q loss
finance.yahoo.com - May 5 at 3:28 PM |
| Somewhat Critical News Coverage Likely to Affect Alnylam Pharmaceuticals (ALNY) Share Price
www.americanbankingnews.com - May 4 at 3:54 PM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Expected to Announce Quarterly Sales of $27.63 Million
www.americanbankingnews.com - May 3 at 3:16 PM |
| Alnylam Pharmaceuticals, Inc. (ALNY) to Release Quarterly Earnings on Friday
www.americanbankingnews.com - May 3 at 7:36 AM |
| -$1.22 Earnings Per Share Expected for Alnylam Pharmaceuticals, Inc. (ALNY) This Quarter
www.americanbankingnews.com - May 1 at 1:51 PM |
| Positive Press Coverage Extremely Likely to Affect Alnylam Pharmaceuticals (ALNY) Share Price
www.americanbankingnews.com - May 1 at 11:44 AM |
Alnylam Pharmaceuticals (ALNY) Chart for Tuesday, May, 23, 2017
